Waters Launches Cyclic IMS P20 MS for Advanced Disease Detection
Event summary
- Waters Corporation launched the Cyclic IMS P20 Mass Spectrometer on June 1, 2026, at the 74th ASMS Conference.
- The new system offers a >10x increase in MS/MS sensitivity and a 50% extended upper mass range to over 100 kDa.
- Integrated MALDI XS and DESI XS imaging enables direct visualization of molecules in tissue for disease mechanism studies.
- The Cyclic IMS P20 MS will be available globally beginning September 2026.
The big picture
Waters' Cyclic IMS P20 MS addresses growing demand for higher-resolution structural and spatial omics tools in biopharmaceutical R&D. The system's ability to detect subtle molecular differences earlier could accelerate therapeutic breakthroughs, particularly for complex diseases driven by protein misfolding. This launch positions Waters as a leader in next-generation mass spectrometry, potentially expanding its market share in high-end analytical instrumentation.
What we're watching
- Adoption Pace
- How quickly academic and industry researchers will integrate the Cyclic IMS P20 MS into their workflows.
- Competitive Response
- Whether competitors like Thermo Fisher or Bruker will accelerate development of comparable technologies.
- Revenue Impact
- The contribution of Cyclic IMS P20 MS sales to Waters' fiscal 2027 results.
Related topics